EAU 2021: updates in testicular cancer

Whilst advances in diagnostic procedures, radiotherapies, cisplatin-based chemotherapy, and surgery have meant that testicular cancer is curable in around 95% of cases, the side effects of radiotherapy and chemotherapy can significantly impact quality-of-life (QoL) outcomes for patients treated for testicular cancer in both the short and long term. Currently, much research is investigating how novel approaches to treatment and monitoring can be used and incorporated to improve QoL outcomes for patients treated for testicular cancer. In this podcast, Tahlita Zuiverloon, MD, PhD, of the Erasmus MC Cancer Institute, Rotterdam, The Netherlands; Peter Albers, MD, University of Düsseldorf, Düsseldorf, Germany; and Matthew Murray, MB, BChir, PhD, Cambridge University Hospitals NHS Foundation Trust, discuss key updates in the field of testicular cancer, as presented at the 2021 European Association of Urology (EAU) Virtual Meeting, including research on the use of MRI versus CT, surgery in metastatic disease and microRNA biomarkers.